REGENXBIO settles GSK sublicense fee dispute for $10M

REGENXBIO Inc.

Company will pay $10.0M to GSK within 3 business days for alleged underpayment of sublicense fees.
Settlement includes mutual releases of past claims and certain future claims under the 2009 license agreement.
Company retains existing allocation methodology for future sublicense fee payments to GSK.
Dispute covered sublicense fees and royalties on amounts received from sublicensees.

Key facts

Extracted from this filing and checked against the source text.

Material Agreements SEC 8-K Item 1.01/1.02 confidence 0.9

REGENXBIO Inc. entered into Settlement and Release Agreement with GlaxoSmithKline LLC valued at $10.0 million (effective 2026-03-18).

Action: entry
Agreement: settlement
Counterparty: GlaxoSmithKline LLC
Value: $10.0 million
Effective: 2026-03-18

Exact text from the filing

On March 18, 2026, REGENXBIO Inc. (the “Company”) entered into a Settlement and Release Agreement (the “Settlement Agreement”) with GlaxoSmithKline LLC (“GSK”) to resolve non-binding mediation related to the License Agreement dated March 6, 2009, as amended on April 15, 2009, between GSK and the Company (as amended, the “GSK-REGENXBIO Sublicense”).

View on SEC.gov

Browse all material agreements →

REGENXBIO Inc. filing history →

Source: SEC EDGAR

accession 0001193125-26-117913

view filing index on sec.gov

view primary document

Machine-readable: JSON · Markdown · Plain text

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.